HUTCHMED (NASDAQ:HCM) Hits New 52-Week Low – Time to Sell?

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) shares reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $11.70 and last traded at $11.70, with a volume of 13606 shares. The stock had previously closed at $11.99.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Bank of America decreased their target price on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, March 10th. Weiss Ratings lowered HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 1st. Finally, Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $16.88.

HUTCHMED Trading Down 2.0%

The company has a debt-to-equity ratio of 0.05, a current ratio of 4.96 and a quick ratio of 4.83. The business has a 50-day simple moving average of $13.97 and a 200-day simple moving average of $14.29.

HUTCHMED (NASDAQ:HCM) last posted its quarterly earnings results on Friday, March 6th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.50 by ($2.49). The business had revenue of $135.42 million during the quarter, compared to the consensus estimate of $290.50 million. Equities analysts forecast that HUTCHMED will post 0.41 EPS for the current fiscal year.

Institutional Investors Weigh In On HUTCHMED

Hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. raised its position in HUTCHMED by 131.5% in the 4th quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock valued at $103,000 after purchasing an additional 4,378 shares in the last quarter. Ameriprise Financial Inc. raised its position in HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after purchasing an additional 698 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its position in HUTCHMED by 12.1% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock valued at $273,000 after purchasing an additional 1,873 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of HUTCHMED by 17.3% in the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after acquiring an additional 3,035 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of HUTCHMED by 34.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after acquiring an additional 5,538 shares during the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.